Evaluation of the effect of empagliflozin administration on reproductive and metabolic characteristics in rats with polycystic ovary syndrome

[D. D. Rakić]

137 listova

Sindrom policističnih jajnika (engl. Polycystic Ovary Syndrome - PCOS) je česta multifaktorska endokrinopatija u reproduktivnom dobu žene, koje je povezan sa neplodnošću i metaboličkim poremećajima. U poslednje vreme dosta je istraživana etiopatogeneza ovog poremećaja, kao i modulacija terapijskog pristupa. Još uvek postoje mnoge nesuglasice u izboru terapije, a metformin predstavnja jedan od najčešće primenjivanih agenasa u terapiji PCOS. Obzirom da postoji povezanost metaboličkih poremećaja i PCOS, glikemijski status veoma je važan kod ovih pacijenata, te inhibitori natrijum glukoznog kotransporta tipa 2 (SGT2I) predstavljaju potencijalno ohrabrujući, novi terapijski pristup. Pokazano je da ovi lekovi poboljšavaju metabolizam glukoze, smanjuju količinu masnog tkiva, smanjuju oksidativni stres i štite kardiovaskularni sistem. Ovi podaci su nas naveli da istražimo efekte primene empagliflozina (EMRA) u PCOS modelu kod pacova i uporedimo ih sa efektima metformina. Potvrdili smo da EMRA deluje pozitivno na somatometrijske parametre, metabolizam glukoze i lipida, nivo polnih hormona, smanjuje oksidacioni stres, poboljšava ovarijalnu funkciju i morfologiju, kao i morfologiju uterusa. Primena EMRA u dozama od 5 mg/kg, 15 mg/kg i 45 mg/kg tokom 4 nedeljnj tretmana pobošava metabolički i reproduktivni status u PCOS modelu pacova izazvanog primenom estradiol-valeratoa i režima ishrane bogate mastima. Najbolji efekti su ostvareni u grupama koje su dobijale srednju i najveću primenjenu dozu EMRA, što je bilo uporedivo sa efektima metformina. Ovi rezultati mogu navesti na dalja klinička istraživanja primene EMRA kod pacijentkinja sa PCOS.

Polycystic Ovary Syndrome (PCOS) is a common multifactorial endocrinopathy in women of reproductive age, associated with infertility and metabolic disorders. Recently, much research has focused on the etiopathogenesis of this disorder and the modulation of therapeutic approaches. There are still many controversies in the choice of therapy, and metformin is one of the most commonly used agents in PCOS therapy. Considering the link between metabolic disorders and PCOS, glycemic status is crucial in these patients, and sodium-glucose cotransporter type 2 inhibitors (SGLT2Is) represent a potentially promising new therapeutic approach. These drugs have been shown to improve glucose metabolism, reduce adipose tissue, decrease oxidative stress, and protect the cardiovascular system. These data prompted us to investigate the effects of empagliflozin (EMPA) in a PCOS rat model and compare them with the effects of metformin. We confirmed that EMPA positively affects somatometric parameters, glucose and lipid metabolism, levels of sex hormones, reduces oxidative stress, improves ovarian function and morphology, as well as uterine morphology. Administration of EMPA at doses of 5 mg/kg, 15 mg/kg, and 45 mg/kg during 4-week treatment improved metabolic and reproductive status in a PCOS rat model induced by estradiol valerate and a high-fat diet. The best effects were achieved in groups receiving the middle and highest applied doses of EMPA, which was comparable to the effects of metformin. These results may prompt further clinical research on the use of EMPA in patients with PCOS.

Sindrom policističnih jajnika, metformin, empagliflozin, pacov, inhibitori kotransporta natrijuma i glukoze tipa 2, metabolički sindrom, reprodukcija

Polycystic Ovary Syndrome, metformin, empagliflozin, rats, sodium-glucose cotransporter type 2 inhibitors, metabolic syndrome, reproduction

618.11

Policistični jajnici

Tekst